Tirzepatide: How a Dual GIP/GLP-1 Agonist Is Studied

Tirzepatide is a synthetic peptide that switches on two incretin receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Few metabolic peptides have been studied as heavily in people. This summary reports what those trials found. It does not describe any use of research-grade material, which is for laboratory Research Use Only.

Two incretin receptors at once

Incretins connect the gut to insulin signaling. Tirzepatide was built to act on both the GIP and GLP-1 receptors, which is why it is called a dual agonist. Reviews cover how this combined action is studied for glucose and energy metabolism (Nauck & D'Alessio, Cardiovasc Diabetol, 2022). [1] Pharmacology work also describes it as an imbalanced, biased agonist across the two receptors, and that remains an active area of mechanism research.

The human trial record

Tirzepatide has an unusually large human research base. The SURPASS program tested it in people with type 2 diabetes against comparators (Rosenstock et al., Lancet, 2021). [2] The SURMOUNT-1 trial looked at body-weight outcomes in obesity (Jastreboff et al., N Engl J Med, 2022). [3] These are large randomized trials, which explains why tirzepatide comes up so often in metabolic research discussions.

Approval status

Tirzepatide is an FDA-approved drug: Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for weight management. That approval covers the pharmaceutical products. It does not cover research-grade material.

Note: Human trial data do not turn research material into a medicine or permit human use. Trials use pharmaceutical-grade drug under medical supervision. Research-grade material is for laboratory Research Use Only and is not for human or veterinary use, diagnosis, or treatment.

FAQ

How is tirzepatide different from a GLP-1 agonist like semaglutide?

Semaglutide acts on the GLP-1 receptor only. Tirzepatide acts on both the GLP-1 and GIP receptors. That dual action is what the research treats as its defining feature.

Does the trial data make research material OK to use?

No. Trials use the pharmaceutical product under medical supervision. Research-grade material is Research Use Only and is not for human use.

References

1. Nauck & D'Alessio — tirzepatide dual GIP/GLP-1 agonist review (Cardiovasc Diabetol, 2022)
2. Rosenstock et al. — SURPASS-1 (Lancet, 2021)01324-6)
3. Jastreboff et al. — SURMOUNT-1, tirzepatide & obesity (NEJM, 2022)
4. Retatrutide guide (triple-receptor agonist)